Systemic lupus erythematosus (SLE) is
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting various tissues. Involvement of B and T cells as well as increased cytokine levels have been associated with disease manifestation.
Recently, we demonstrated that mice with epidermal loss of JunB (JunB ⌬ep ) develop a myeloproliferative syndrome (MPS) due to high levels of G-CSF which are secreted by JunBdeficient keratinocytes. In addition, we show that JunB ⌬ep mice develop a SLE phenotype linked to increased epidermal interleukin 6 (IL-6) secretion. Intercrosses with IL-6-deficient mice could rescue the SLE phenotype. Furthermore, we show that JunB binds to the IL-6 promoter and transcriptionally suppresses IL-6. Facial skin biopsies of human SLE patients similarly revealed low JunB protein expression and high IL-6, activated Stat3, Socs-1, and Socs-3 levels within lupus lesions. Thus, keratinocyte-induced IL-6 secretion can cause SLE and systemic autoimmunity. Our results support trials to use ␣-IL-6 receptor antibody therapy for treatment of SLE.
epidermis ͉ IL-6R ͉ systemic lupus erythematosus I nterleukin 6 (IL-6) is a multifunctional cytokine exerting diverse effects on different organs in autocrine, paracrine, and endocrine fashion (1, 2) . The major sources of IL-6 are reported to be monocytes, fibroblasts, and endothelial cells (3) . IL-6 is bound as a dimer within an IL-6R␣ hexameric ligand-receptor complex (4) and can induce Ig production, T-cell maturation, as well as glomerulonephritis and plasmocytosis (5) (6) (7) . SCID-IL-6 transgenic mice do not show such abnormalities (8) . A role of IL-6 for different inflammatory autoimmune diseases such as rheumatoid arthritis or Crohn's Disease has been established. Increased levels of IL-6 and cytokines such as TNF-␣, IL-1, and IL-18 have been observed in systemic lupus erythematosus (SLE) (9, 10) . SLE is characterized by the presence of autoimmune antibodies and immune complexes, which form deposits in various tissues and can cause severe tissue damage (11) .
Activator protein 1 (AP-1) is a dimeric transcription factor, consisting of variable combinations of members of the jun (jun, junB, junD), fos (fos, fosB, fra-1, and fra-2), ATF, and maf protein families (12) . Jun proteins were recognized as important regulators of cytokine expression and immune response (13) . The function of Jun proteins within the AP-1 complex crucially depends on the cellular context. Mice with induced epidermal deletion of c-jun and junB develop hallmarks of psoriasis (14) . Keratinocytes JunB ⌬ep mice secrete high levels of G-CSF, which leads to a myeloproliferative syndrome (MPS) phenotype (15) . In addition, JunB ⌬ep mice develop SLE with increased epidermal IL-6 levels, skin lesions, and systemic disease including nephritis. The glomerulonephritis and skin disease in JunB ⌬ep mice is attenuated by crossing to IL-6-deficient mice. In addition, JunB binds to the IL-6 promoter and transcriptionally downregulates IL-6 expression. Within lupus lesions of facial skin biopsies from human SLE patients, we measured reduced JunB and elevated IL-6 protein expression levels. Therefore, keratinocyte-induced IL-6 secretion is sufficient to cause a SLE phenotype. Our data provide a mechanism for the development of SLE and emphasize the use of antibodies directed against the IL-6 receptor for the treatment of SLE.
Results

SLE Phenotype by JunB ⌬ep and Rescue by IL-6
Depletion. We here demonstrate that JunB ⌬ep mice develop a SLE phenotype dependent on increased epidermal IL-6 secretion ( Fig. 1 B and H) . Therefore, we crossed JunB ⌬ep mice to IL-6 Ϫ/Ϫ mice (16) to investigate the effect of IL-6 on the phenotype resulting from the loss of JunB. The cutaneous affection of JunB ⌬ep mice was characterized by spontaneous dermatitis of ears, snouts, upper thorax region and paws starting at the age of 3 months postpartum (Fig. 1B) . JunB ⌬ep IL-6 Ϫ/Ϫ mice had a milder thickening of the skin than JunB ⌬ep mice, with only mild hyperkeratosis and inflammatory infiltrates ( Fig. 1 A-C and Fig. S1 A-C) (15) . Microscopic screening of internal organs revealed plasmocytosis in JunB ⌬ep mice, however, the lymph nodes of controls and JunB ⌬ep IL-6 Ϫ/Ϫ mice showed normal architecture without increased plasma cell count (Fig. S1 D-F) . JunB ⌬ep mice developed linear ␣-IgG-immunofluorescence at the dermo-epidermal junction, referred to as ''lupus band,'' which was not observed in JunB ⌬ep IL-6 Ϫ/Ϫ mice and controls ( Fig. 1 D-F ). IL-6 protein expression was elevated in JunB ⌬ep mice, whereas in controls and JunB ⌬ep IL-6 Ϫ/Ϫ mice, IL-6 expression was not detectable ( Fig. 1  G-I ). JunB ⌬ep mice developed an immunocomplex glomerulonephritis (IC-GN), which was characterized by mesangial hypercellularity, lobulation of the glomerular tuft with basement membrane thickening, endocapillary hypercellularity, and luminal obstruction by immuno complex deposits. JunB ⌬ep IL-6
and control mice had no such immune complexes, shown by acid fuchsin orange G-stain (AFOG) staining ( Fig. 1 J-L) . Electron microscopy (ELMI) revealed electron-dense immune deposits in mesangial and subendothelial regions concomitantly to podocyte foot process effacement in the majority of glomerular capillary loops. This was not observed in JunB ⌬ep IL-6 Ϫ/Ϫ and control mice (Fig. S1 J-L) . Heterogeneity and immune complex composition resembled renal lesions as observed in human SLE nephritis (Fig. S1 M-P) . Macroscopically, the small and atrophic Author contributions: L.K. designed research; P. Pflegerl, P.V., B.H., M.S., G.S., A.M., A.S., G.E., R.M., and E.F.W. performed research; P.W., T.K., and E.F.W. contributed new reagents/ analytic tools; P. Pflegerl, R.Z., E.J., G.S., P. Petzelbauer, T.K., and L.K. analyzed data; and L.K. wrote the paper.
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appearance of JunB ⌬ep kidneys was rescued to normal size in JunB ⌬ep IL-6 Ϫ/Ϫ mice (Fig. 1M ). JunB ⌬ep mice showed increased albuminuria of up to 170 ng/dL albumin in the urine compared to controls and JunB ⌬ep IL-6 Ϫ/Ϫ mice (Fig. 1N ). Antinuclear autoantibodies (ANA) are a hallmark of human SLE (17) . Most SLE patients develop autoantibodies (AutoABs) against chromatin components directed either against a single component or the complete nucleosome itself. ANAs are detected in the serum of JunB ⌬ep mice, but not in sera of controls and JunB ⌬ep IL-6 Ϫ/Ϫ mice ( Fig. S1 G-I ). AutoABs to histones display typical features of a T-cell-dependent antigene (AG)-driven immune response like Ig class switching (18). Histones are considered as the main source for T cell AGs in human SLE as well as murine SLE models (19, 20) . Histological features of the SLE observed in JunB ⌬ep mice were accompanied by high autoantibody levels against histones (H1, H2A, H2B, H3, and H4) and SmD (Fig. 1O) . JunB ⌬ep IL-6 Ϫ/Ϫ mice neither showed any ␣-histone-nor ␣-SmD-antibodies as opposed to JunB mice. Anti-histone ABs first occurred at 4-5 months and peaked around 6-12 months of age in JunB ⌬ep mice. Antinuclear SmD Abs, which are also typical for murine and human SLE (21, 22) , were detected after 5 months. Ablation of IL-6 in JunB ⌬ep IL-6 Ϫ/Ϫ mice could eliminate the systemic autoimmune disease observed in JunB ⌬ep mice and the early mortality observed in JunB ⌬ep IL-6 Ϫ/Ϫ mice (Fig. 1P ). Since SLE is commonly exacerbated by sun exposure, we challenged JunB ⌬ep mice with UV-irradiation. UV-irradiation enhanced severity of lupus-like skin lesions on histomorphological and immunohistochemical levels compared to controls ( Fig.  2 A-D) . Epidermal thickness of JunB ⌬ep was not significantly affected compared to controls ( Fig. S2 A-E) . The IC-GN in JunB ⌬ep mice was accompanied by a tubulo-interstitial nephritis, dominated by perivascular CD3 ϩ T-cell-rich infiltrates compared to controls (Fig. 2 E and F and Fig. S2 F and G) . Examination of the liver and lung revealed inflammatory perivascular infiltrates that also contained abundant CD3 ϩ T-lymphocytes (Fig. 2 G-J and Fig. S2 H-K) . Furthermore, JunB ⌬ep mice developed swelling of paws with functional articular impairment, synovial proliferation, and incipient inflammatory infiltration of the synovial membrane.
Systemic occurrence of immune complexes was paralleled by a marked increase of activated CD138 ϩ plasma cells in lymph nodes and spleen, and increased serum levels of IgE Abs and Fc receptor for IgE (FcRI) antisera, which were reported to be elevated in SLE patients (Fig. S3 A-C) (23) . All other Ig levels were in normal range (Fig. S3D) . To screen for mediators between JunB ⌬ep keratinocytes and the immune system, we performed serum ELISA of major Th1-and Th2-specific cytokines and in vitro expression analysis of isolated JunB ⌬ep keratinocytes. FACS-ELISA revealed a significant increase of IL-6 protein expression compared to controls, while other major cytokines such as IL-1␣, IL-2, IL-5, IL-10, INF-␥, TNF-␣, GM-CSF, IL-4, and IL-17 were in normal range (Fig. S4A) . Serum concentration of IL-6 was 4-fold increased, and G-CSF was more than 10-fold increased, which are secreted by JunB-deficient keratinocytes (15) . IL-6 can induce T-or B-cell differentiation (1, 24) , and IL-6 knockout mice show reduced antigen-specific IgG1, IgG2a, and IgG3 levels upon immunization (25) . Thus, we generated compound mouse models lacking JunB proteins in the epidermis and systemically IL-6 or G-CSF. JunB ⌬ep G-CSF Ϫ/Ϫ still show the SLE phenotype ( Fig. S4 I and E) , indicating that G-CSF is not responsible for the autoimmune phenotype. IL-6-Jak1-Stat3 activation promotes plasma B-cell differentiation either directly (26) or indirectly through CD4 ϩ T helper cells (27) . To investigate the role of lymphocytes in the development of local and systemic autoimmune alterations, JunB ⌬ep mice were crossed with Rag2 Ϫ/Ϫ mice. Rag2 deficiency in mice leads to a loss of T-and Blymphocytes, and JunB ⌬ep Rag2 Ϫ/Ϫ mice had no symptoms of systemic autoimmunity. The glomerula of JunB ⌬ep Rag2 Ϫ/Ϫ kidneys appeared normal. Of note, these mice displayed mild epidermal thickening with local granulocyte infiltration of the skin (Fig. S4 D  and H) . These data confirm the important role of lymphocytes in SLE-like disease in JunB ⌬ep mice. In addition, we performed Socs-1 and Socs-3 immunohistochemistry stainings on wild-type and JunB ⌬ep skin sections (Fig. S4 J-M) to investigate the role of IL-6/pStat3 target gene induction more closely. JunB ⌬ep and human SLE patients skin displayed strong Socs-1 and Socs-3 protein expression compared to epidermis of wild-type mice and human controls. This finding indicates involvement of Socs-1 and Socs-3 in SLE pathology.
IL-6 Expression Is Directly Regulated by JunB.
Since JunB is a tumor suppressor antagonizing for example c-Jun/Fos heterodimers, we suspected that overexpression of IL-6 by JunB ⌬ep keratinocytes resulted from loss of IL-6 promoter repression by JunB containing AP-1 complexes. The IL-6 gene promoter contains a functional AP-1 binding site (28) . We performed chromatin immunoprecipitation (ChIP) with an antibody against JunB in keratinocytes isolated from control and JunB ⌬ep mice. The conserved AP-1 binding site is located in the IL-6 promoter (Ϫ296 bp to Ϫ290 bp; sequence: tgagtca) (Fig. 3A) . A 4-fold stronger ChIP signal was observed using skin from control mice as opposed to JunB ⌬ep mice using primers that amplify a product with the AP-1 binding site (Fig.  3B) . Control Ab ChIP assays did not result in significant enrichment. Next, we cloned a murine IL-6 promoter fragment containing the AP-1 binding site in front of a luciferase gene. Since B cells are difficult to be transiently transfected, we used human HeLa cervix carcinoma cells, which contain significant amounts of AP-1 complexes and transfected them with pIL-6. HeLa cells were either cotransfected with or without a JunB expression plasmid. Interestingly, a JunB-dependent repression of the IL-6 promoter activity in presence of inflammatory IL-6 cytokine conditions was observed (Fig. 3C) . Our data suggest that JunB acts as a repressor on the IL-6 promoter in presence of high IL-6 concentrations. Loss of JunB Correlates with Human SLE. To compare our findings in JunB ⌬ep mice, we performed histological analyses of SLE patient's skin biopsies and controls (Fig. 4 A and B) . The morphological alterations were very similar to those found in JunB ⌬ep mice (Fig. 4 C and D) . Immunhistochemical (IHC) analysis of JunB, IL-6, and IL-6R␣ chain and py-Stat3 were performed from human skin biopsy specimens. Protein expression was measured by defining the epidermis as region of interest (ROI), thereby excluding inflammatory cells found in the dermis, using automated cell acquisition and quantification software (Histoquest). Strong nuclear JunB immunoreaction was found in normal human facial skin (Fig. 4E ). Skin specimens of SLE patients revealed a reduced JunB expression in the nuclei of keratinocytes in seven of eight cases (Fig. 4 F and G) . Staining for IL-6 was severely reduced in the epidermis of SLE patients compared to normal controls (Fig. 4 H-J) . IL-6R␣ was expressed at very low levels in the epidermis of controls. IL-6R␣ staining of SLE patients revealed a strong cytoplasmatic expression, which was strongest in basal and subbasal keratinocytes as compared to controls (Fig. 4 K-M) . A weak cytoplasmic py-Stat3 immunoreaction was found in the keratinocytes (Fig. 4N ) of controls, whereas SLE patients had a strong immunostaining for py-Stat3 predominantly in the basal layer of the epidermis (Fig.  4 O-P) . Quantification of the expression data for JunB, IL-6, IL-6R␣, and py-Stat3 revealed statistically a high and significant expression in SLE patients compared to normal controls.
Discussion
Our data provide a link between loss of epidermal JunB and the development of SLE both in human patients and in an animal model, which can be helpful for further studies of SLE. The direct regulation of IL-6 by JunB emphasizes IL-6 as a target for anti-cytokine therapy in human SLE patients. IL-6 has been suggested to play a role in the development of SLE (21) , and especially in patients with Lupus-nephritis, IL-6 levels are significantly increased (29, 30) . In addition it was shown that IL-6 can experimentally deteriorate lupus nephritis (7) and that IL-6R blockage can improve it (31) . In contrast, we did not find evidence for involvement of other Stat3-activating cytokine or growth factor receptor systems. We looked in detail for gp130 family members (1-3) such as the receptor chains for oncostatin M (OSMR) or leukemia inhibitory factor receptor (LIFR), since these are not restricted to specific organs such as caliotrophin (heart) or ciliary neurotrophic factor (neuronal tissue). In contrast to the strong upregulation of the IL-6R␣ chain with strong IL-6 expression in the epidermis, we did not find significant expression levels of the OSMR and LIFR. We exclude also a role for epidermal G-CSF production through the use of G-CSF knockout mice, which did not complement the SLE phenotype upon epidermal JunB loss.
Activated Stat3 can cause an autocrine upregulation of the IL-6R-pYStat3 axis (32) , and also IL-6 production was traced to the epidermis causing states of chronic inflammation with skin disease. Moreover, IL-6 is a immunomodulatory cytokine that was systemically high in the serum. It controls plasma B-cell differentiation, and it influences also T helper cell cytokine production through Stat3-dependent signaling (1, (25) (26) (27) . Stat3 isoforms are known to cooperate with c-Jun or JunD proteins specifically (33) . In addition, Stat3 response elements are often found close to AP-1 response elements and the c-fos oncogene or the junB tumor suppressor protein were identified as transcriptional targets of activated Stat3 (2-3). Here, we show that less JunB proteins are expressed upon strong Stat3 activity in human skin biopsies. This finding could indicate a difference in Stat3 isoform expression, which needs further investigation, since the pY-Stat3 antibody staining cannot distinguish between isoforms. Overall, our data suggest that IL-6 activates Stat3 strongly via tyrosine (Fig. 4) phosphorylation, which pinpoints to a high expression and activation of Stat3␣. Interestingly, we found increased SOCS-1 and SOCS-3 protein expression (Fig. S4 K and M) in autoimmune diseased tissues, which are known target genes of IL-6 activated Stat3. The strong expression of Socs proteins change global phosphotyrosine-dependent signaling, since Socs proteins target phosphotyrosine proteins, such as kinases to the proteasome (2) . If genetic deletion of Socs-1 or Socs-3 proteins would be beneficial for interfering with SLE phenotype, this could be a valuable future research direction.
Recently, with the rise of biotherapies, IL-6R antibodies have turned into the center of interest to block B-cell activity in autoimmune diseases (34) . A variety of anti-IL-6R antibodies have already been applied for the treatment of autoimmune diseases (35) such as rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (JIA) adult Still's disease, Castleman's disease, and Crohn's disease (35) . We here highlight the possibility, that IL-6 overexpression can be induced by deregulation of JunB expression in the epidermis. In addition, IL-6 activation in the epidermis is sufficient to induce autoABs production and SLE-like disease. Therefore, our data provide molecular evidence for the development of SLE and bring IL-6 action to the center stage. We propose IL-6R antibodies as a promising tool for the treatment of human SLE. JunB ⌬ep mice are a good model to go to clinical test phase with IL-6R antibodies in the future. . HeLa cells were either cotransfected with pCDNA4hismaxJUNB (JunB) or pCDNA4hismaxA (vec) together with either pIL-6 or pGL3 empty vector for control purpose. Twenty-four hours later, luciferase-and ␤-gal activity (expressed from a routinely cotransfected ␤-gal expression vector) was measured. Luciferase expression from two replicates, normalized to ␤-gal expression was plotted, and error bars are given, represent Ϯ SD. Relative normalized luciferase expression was below detection limit from promoterless pGL3-basic plasmid, while intact luciferase expression from pIL-6 was abrogated by ectopic JunB expression from pCDNA4hismaxJUNB (C).
Materials and Methods
Mice. Mice harboring a floxed JunB allele were generated by targeted homologous recombination as previously described. For conditional deletion of JunB in the skin, JunB f/f mice were crossed to K5-Cre2 transgenic mice (15) . IL-6 Ϫ/Ϫ mice were purchased from the Jackson Laboratory (16) . The genetic background of JunB f/f and K5Cre2 mice was C57BL/6/129SV, while IL-6 Ϫ/Ϫ and Rag2 Ϫ/Ϫ mice were kept in a C57Bl6 background. Mice were genotyped by PCR, and if not otherwise stated, only 3-to 6-month-old littermates were used for the experiments. Mice were housed with alternating 12-h light and dark cycles under specific pathogen-free conditions according to the institutional guidelines of the Medical University Vienna, Austria. Detection of Autoantibodies and ELISA. ANA were detected by indirect immunofluorescence microscopy on Hep-2 cells (Hemagen) according to the manufacturer's instructions using FITC-conjugated goat-anti-mouse IgG (Dako) as secondary Ab and human sera as positive controls. Autoreactivities against nuclear proteins were analyzed by immunoblotting employing HeLa nuclear extracts as described (36) . Nitrocellulose membranes were cut into strips and blocked (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 3% nonfat dried milk) for 1 h at room temperature. Strips were then incubated with serum (1:50), washed, and subsequently incubated with alkaline phosphatase conjugated anti-mouse IgG secondary antibody (1:2,500; Accurate Chemical and Science Corporation). A recently established immunoblotting assay (36) was used for determination of antibodies to individual histones H1, H2A, H2B, H3, and H4 employing highly purified calf thymus histones (Roche Diagnostic GmbH). Additionally and for confirmation of immunoblotting results, sera were analyzed by line immunoassay (Innogenetics) for the presence of antibodies against the antigens SmB, SmD, U1-70K, U1-A, U1-C, Ro (60-and 52-kDa proteins), La, topoisomerase I, Jo1, centromere protein B, ribosomal P protein, and histones. Human autoimmune sera with known specificities served as positive controls as described (17) .
Antibodies to nucleosomes were measured by the anti-chromatin ELISA obtained from Inova Diagnostics. Sera were diluted 1:100 and incubated with HRP-conjugated goat anti-mouse IgG (1:20,000; Jackson Immunoresearch). The cytokine serum profile of JunB ⌬ep and JunB f/f control mice was analyzed by ELISA (R&D Systems).
Chromatin Immunoprecipitation. Isolation of JunB f/f and JunB ⌬ep keratinocytes was performed as described (14) . Keratinocytes were cultured in Costar 12-well plates coated with collagen IV. CHIP assays of these keratinocyte cultures were performed with a CHIP kit (Upstate). Briefly, 2-3 ϫ 10 7 cells were cross-linked with 1% formaldehyde, washed in PBS, and lysed in SDS lysis buffer. Chromatin was fragmented by sonication and precleaned with protein A agarose. Samples were incubated with anti JunB (E11404, 0.2 g/L; Springbio) or unspecific rabbit IgG antibodies (AXELL), and complexes were immunoprecipitated with protein A agarose. Protein-DNA complexes were eluted from the antibodies with 1% SDS, 0.1 M NaHCO 3, and DNA-protein interactions were reversed by addition of 5 M NaCl and heating to 65°C for 4 h. Proteins were digested with proteinase K, and the remaining DNA was purified by phenol/chloroform extraction. Site-specific PCR was carried out using a specific primer pair, amplifying the IL-6 core promoter region between bp Ϫ321 (forward primer: ttcccatcaagacatgctca) and bp Ϫ210 (reverse-primer: aggaaggggaaagtgtgctt), which contains the AP-1 binding site. Each ChIP experiment was carried out at least three times with similar results.
Plasmids. The pIL-6 plasmid was constructed using a 303-bp PCR product amplified from murine Ba/F3 cells cDNA using the primers pIL-6fw: 5Ј-agcggtttctggaattgact-3Ј, and pIL-6re: 5Ј-gaagagtgctcatgcttcttagg-3Ј (murine Refseq genomic IL-6) (37). A XhoI/KpnI fragment was cloned into the pGL3-basic luciferase plasmid-vector (Promega). The ␤-galactosidase (␤-gal) expression vector used was pMIR-REPORT ␤-Gal expression plasmid (p␤-Gal) from Ambion. The JunB expression vector was a pCDNA4hismaxB (pJUNB) from Invitrogen were the murine JunB coding sequence was introduced (courtesy Juliane Strauss Technical University, Graz, Austria).
Luciferase Assay. HeLa cells were grown in 6-well plates in DMEM supplemented with 10% (vol/vol) FBS (FBS), and transfected using Lipofectamine 2000 (Invitrogen). Moreover, cells were incubated in DNA-Lipofectamine 2000 complex containing medium for no more than 1 h. The following amounts of plasmids were used for transfection per well: pJUNB or pVEC (2 g); pIL-6 or pGL3 (1 g); and p␤-Gal (0.1 g). Twenty-four hours after transfection, cells were harvested by trypsinization. Twenty-five percent of the cells were subsequently used for analysis of ␤-gal activity, and 25% were used for analysis of luciferase activity using LUMI-STAR from BMG-LabTech and the BetaGlo kit and the OneGlo kit from Promega.
